Clinical Study
Long-Term Safety of Anti-TNF Adalimumab in HBc Antibody-Positive Psoriatic Arthritis Patients: A Retrospective Case Series of 8 Patients
Table 3
Previous reports about anti-TNF use in HBV active/inactive/occult carriers with psoriatic disease.
| Study | Study type | PsA/Pso patients | Patients’ categories | Premedication | Anti-TNF | Followup period | HBV reactivation |
| Cassano et al. 2011 [17] | R | 34 PsA 28 PsO | OC | No | 44 ETA 10 ADA 8 IFX | About 4 years | Reappearance of HBsAg without detectable HBV-DNA in 1 patient | Prignano et al. 2011 [18] | R | 11 PsO | OC | No | ETA | 7.8 months | No viral reactivation | Cho et al. 2012 [19] | R | 5 PsA 2 PsO | 2 IC 5 AC | 1 patients had lamivudine and then entecavir | 1 ADA 6 ETA | 26.6 months (range 14–45) | 3 patients had HBV reactivation | Fotiadou et al. 2011 [20] | R | 7 PsO | IC | Lamivudine | 3 ADA 3 ETA 1 IFX | 6–24 months | 1 patient receiving IFX had increase of viral load up to 600 IU/mL |
|
|
Psa: psoriatic arthritis; PsO: psoriasis; R: retrospective; OC: occult carrier; IC: inactive carrier; AC: active carriers; ADA: adalimumab; ETA: etanercept; IFX: infliximab.
|